<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02241512</url>
  </required_header>
  <id_info>
    <org_study_id>STU 082014-033</org_study_id>
    <nct_id>NCT02241512</nct_id>
  </id_info>
  <brief_title>IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis</brief_title>
  <official_title>IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced endoscopic technique
      utilized to diagnose and treat pathologic conditions involving the ducts draining the liver
      and pancreas. Post-ERCP pancreatitis (PEP) is the most common complication following ERCP and
      occurs in approximately 11% of children undergoing the procedure. By definition it leads to
      prolongation of hospital stay or delays in care and rarely can result in long-term morbidity
      or even death. Recent adult trials have demonstrated prevention of PEP with administration of
      rectal nonsteroidal anti-inflammatory drugs (NSAIDS). To date, no studies have been performed
      in children thus no &quot;gold standard&quot; or even commonly accepted method of preventing PEP in the
      pediatric population exist. Studying an IV NSAID such as ibuprofen has distinct advantages
      over rectally administered NSAIDs in the pediatric population in that it would allow for more
      consistent weight based dosing and would have more predictable absorption compared to
      suppository. Thus, this project proposes a pilot study evaluating the effectiveness of IV
      ibuprofen at preventing PEP in the pediatric population. The design of the proposed study is
      a prospective randomized double-blind trial comparing IV Ibuprofen to placebo controls
      (normal saline) at the time of procedure in patients undergoing ERCP at Children's Medical
      Center Dallas over a two-year period. The primary outcome measurement will be development of
      PEP. Post-ERCP bleeding and change in pre- and post- procedural pain scores will also be
      measured. The hypothesis is that IV Ibuprofen administered at the time of ERCP will decrease
      rates of post-ERCP pancreatitis in pediatric patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of funding
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-ERCP Pancreatitis</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of patients who develop post-ERCP pancreatitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-ERCP Bleeding</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of patients who develop post-ERCP bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Increased Pain Score</measure>
    <time_frame>pre-procedural, 24 hours</time_frame>
    <description>Number of patients with increased pain scores after the procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>24-h Post-ERCP Pain Score</measure>
    <time_frame>pre-procedural, 24 hours</time_frame>
    <description>Pain score recorded 24-hrs after the ERCP was performed as recorded on a 10-point Likert pain scale (0= lowest value, no pain, 10=highest value, severe pain)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Post-ERCP Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose IV normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>Caldolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&lt;=18 years

          -  Undergoing ERCP (defined as cannulation of the major or minor papilla) for any
             indication

        Exclusion Criteria:

          -  Age&gt;18

          -  Pancreatitis within the 72 hours preceding ERCP

          -  Allergy or hypersensitivity to Aspirin or NSAID medications

          -  Pregnancy or breastfeeding mother

          -  Cr &gt;1.4

          -  Gastrointestinal hemorrhage in preceding 72 hours

          -  Heart disease reliant upon a patient ductus arteriosis

          -  History of sickle cell disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Troendle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <results_first_submitted>February 5, 2020</results_first_submitted>
  <results_first_submitted_qc>February 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2020</results_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>David M Troendle</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>post-ERCP pancreatitis</keyword>
  <keyword>pediatric</keyword>
  <keyword>ibuprofen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02241512/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>10 patients excluded after enrollment. 5 did not undergo ERCP and thus did not receive a study drug. 3 did not have study drug available in time for procedure. 2 did not meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibuprofen</title>
          <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
Ibuprofen</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Single dose IV normal saline
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pump malfunction, drug not delivered</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibuprofen</title>
          <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
Ibuprofen</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single dose IV normal saline
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Pain Score</title>
          <description>Baseline pain score on 10-point Likert scale</description>
          <units>units on a Likert scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" lower_limit="0" upper_limit="4.5"/>
                    <measurement group_id="B2" value="2.2" lower_limit="0" upper_limit="4.0"/>
                    <measurement group_id="B3" value="2.6" lower_limit="0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-ERCP Pancreatitis</title>
        <description>Number of patients who develop post-ERCP pancreatitis</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen</title>
            <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
Ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single dose IV normal saline
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Post-ERCP Pancreatitis</title>
          <description>Number of patients who develop post-ERCP pancreatitis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-ERCP Bleeding</title>
        <description>Number of patients who develop post-ERCP bleeding</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen</title>
            <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
Ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single dose IV normal saline
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Post-ERCP Bleeding</title>
          <description>Number of patients who develop post-ERCP bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Increased Pain Score</title>
        <description>Number of patients with increased pain scores after the procedure</description>
        <time_frame>pre-procedural, 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen</title>
            <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
Ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single dose IV normal saline
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Increased Pain Score</title>
          <description>Number of patients with increased pain scores after the procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>24-h Post-ERCP Pain Score</title>
        <description>Pain score recorded 24-hrs after the ERCP was performed as recorded on a 10-point Likert pain scale (0= lowest value, no pain, 10=highest value, severe pain)</description>
        <time_frame>pre-procedural, 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen</title>
            <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
Ibuprofen</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single dose IV normal saline
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>24-h Post-ERCP Pain Score</title>
          <description>Pain score recorded 24-hrs after the ERCP was performed as recorded on a 10-point Likert pain scale (0= lowest value, no pain, 10=highest value, severe pain)</description>
          <units>score on a Likert pain scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>All adverse events were defined by the American Society of Gastroenterology (ASGE) lexicon for endoscopic adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibuprofen</title>
          <description>Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
Ibuprofen</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Single dose IV normal saline
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Post-ERCP Pancreatitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Abdominal pain not related to post-ERCP pancreatitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>post-ERCP bleeding</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <description>ERCP related perforation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <description>Post-ERCP cholangitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Troendle</name_or_title>
      <organization>UT Southwestern</organization>
      <phone>214456-8000</phone>
      <email>david.troendle@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

